Molecular Microbiology (Virology)
Institute of Medical Microbiology and Hygiene
University Regensburg


We aim towards improving quality of life and health across the globe by developing new vaccines from the bench to the clinic.

With our vaccine research, we aim to contribute towards fighting viruses for which no vaccine exists so far (HIV), which are endemic in lower income countries with high fatality rates (Ebola, Marburg, Lassa, Crimean-Congo haemorrhagic fever virus), which have the potential to cause the next pandemic (influenza- and coronaviruses), and which are associated with malignancies (HPV) or severe clinical manifestations in certain risk groups (CMV).

Combined with our research, we strive to qualify our students through an attractive range of courses, bachelor, master and doctoral theses and to make them fit for the primary labour market. Where appropriate, we also endeavour to translate our research results into commercial products and services.


Our vaccine efforts are based on

  • epidemiological data generation and analysis (viral, immunological, B and T cells)
  • a deep understanding of viral replication and pathogenesis
  • cutting edge protein design and manufacturing capabilities
  • platform technologies for optimal delivery of protein-based antigens
  • nonviral and viral
  • testing in non-human primates (cooperation with partners)
  • phase 1 to 2b clinical trials (cooperation with clinical Partners)